Skylark Bio advances hearing loss gene therapy to younger children
Skylark Bio has received unanimous independent safety board support to advance its experimental gene therapy for genetic hearing loss into a younger paediatric cohort in a Phase 1/2 clinical trial.
The Data Safety Monitoring Board (DSMB) recommended progression following a review of safety data from four children aged 2–7 years treated with SKY-GJB2 in the SONIX trial. The next cohort will include children aged nine months to under two years.
The study is the first clinical trial evaluating gene therapy for GJB2-related hearing loss, a leading genetic cause of childhood deafness.
Gene therapy targets underlying cause of deafness
SKY-GJB2 is an investigational, one-time gene therapy designed to deliver a functional copy of the GJB2 gene to supporting cells in the cochlea.
Mutations in GJB2 disrupt the production or function of connexin 26, a protein essential for maintaining the gap-junction network in the inner ear and normal hearing.
There are currently no approved disease-modifying treatments for GJB2-related hearing loss. Existing interventions, including hearing aids and cochlear implants, can provide access to sound but do not address the underlying genetic cause.
Skylark Bio chief executive officer Jodi Cook said: “The DSMB’s recommendation marks an important milestone for the SKY-GJB2 program and supports continued advancement of SONIX into younger children during a critical period of auditory and language development.”
SONIX trial evaluates safety and hearing function
SONIX is a first-in-human, multicentre, open-label Phase 1/2 study involving children aged nine months to seven years with hearing loss caused by GJB2 mutations.
The trial is designed to assess safety and tolerability, alongside preliminary evidence of improved hearing function following a single injection of SKY-GJB2 directly into one cochlea.
The DSMB’s recommendation allows the study to progress to its second cohort, but does not establish whether the treatment improves hearing. Clinical efficacy will need to be assessed through subsequent trial results.
Initial clinical results expected in 2027
Skylark expects to generate preliminary clinical data by the end of 2026, with initial results expected to be presented in 2027.
The company’s pipeline also includes SKY-AS, a gene therapy programme designed to restore UBE3A expression in people with Angelman syndrome, which is progressing through investigational new drug-enabling studies.
A further programme, SKY-PEN, is being developed for SLC26A4-related hearing loss.




